Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules.
Copolymer 1 (Cop 1, poly (Y, E, A, K)) is a random synthetic amino acid copolymer effective in the treatment of relapsing forms of multiple sclerosis (MS). Cop 1 binds promiscuously, with high affinity and in a peptide-specific manner to purified MS-associated HLA-DR2 (DRB1*1501) and rheumatoid arthritis-associated HLA-DR1 (DRB1*0101) or HLA-DR4 (DRB1*0401) molecules. In the present work at least 95% of added Cop 1 could be bound to recombinant "empty" HLA-DR1 and -DR4, and 80% could be bound to HLA-DR2 proteins. Amino acid composition, HPLC profiles, and sequencing patterns of Cop 1 eluted by acid extraction from HLA-DR molecules were similar to those of the unseparated Cop 1. Protruding N-terminal ends of Cop 1 bound to HLA-DR1, -DR2, or -DR4 molecules were then treated with aminopeptidase I, followed by elution, HPLC, and pool sequencing. In contrast to untreated or unbound Cop 1, this material exhibited distinct motifs at some positions with increases in levels of E at the first and second cycles, of K at the second and third cycles, and of Y (presumably at P1 of the bound peptide) at the third to fifth cycles, regardless of the HLA-DR molecule employed. No preference was seen at the following cycles that were mainly A. These first pooled HLA-DR binding epitopes provide clues to the components of Cop 1 that are biologically active in suppressing MS and possibly rheumatoid arthritis.
Fridkis-Hareli
M
M
Department of Molecular and Cellular Biology, Microchemistry Facility, Harvard University, Cambridge, MA 02138, USA.
Neveu
J M
JM
Robinson
R A
RA
Lane
W S
WS
Gauthier
L
L
Wucherpfennig
K W
KW
Sela
M
M
Strominger
J L
JL
D000595:Amino Acid Sequence; D000596:Amino Acids / Q000032:analysis; D000626:Aminopeptidases / Q000737:chemistry; D000906:Antibodies / Q000378:metabolism; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000378:metabolism*; D001665:Binding Sites / Q000276:immunology; D001666:Binding Sites, Antibody; D002851:Chromatography, High Pressure Liquid; D000068717:Glatiramer Acetate; D006684:HLA-DR Antigens / Q000276:immunology / Q000378:metabolism*; D015798:HLA-DR1 Antigen / Q000378:metabolism; D015802:HLA-DR2 Antigen / Q000378:metabolism; D015804:HLA-DR4 Antigen / Q000378:metabolism; D006801:Humans; D009103:Multiple Sclerosis / Q000276:immunology / Q000378:metabolism*; D010446:Peptide Fragments / Q000276:immunology* / Q000302:isolation & purification / Q000378:metabolism*; D010455:Peptides / Q000276:immunology* / Q000302:isolation & purification / Q000378:metabolism*; D011108:Polymers / Q000302:isolation & purification / Q000378:metabolism*; D029701:Saccharomyces cerevisiae Proteins
D000596:Amino Acids; D000906:Antibodies; D006684:HLA-DR Antigens; D015798:HLA-DR1 Antigen; D015802:HLA-DR2 Antigen; D015804:HLA-DR4 Antigen; D010446:Peptide Fragments; D010455:Peptides; D011108:Polymers; D029701:Saccharomyces cerevisiae Proteins; D000068717:Glatiramer Acetate; D000626:Aminopeptidases; C019689:APE1 protein, S cerevisiae